Wockhardt Limited (BOM:532300)

Market Cap	231.44B
Revenue (ttm)	30.01B
Net Income (ttm)	-1.91B
Shares Out	n/a
EPS (ttm)	-12.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,597
Average Volume	30,292
Open	1,433.65
Previous Close	1,404.45
Day's Range	1,407.00 - 1,469.95
52-Week Range	489.20 - 1,678.60
Beta	n/a
RSI	54.76
Earnings Date	May 28, 2025

About Wockhardt

Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram nega...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 2,386
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532300

Financial Performance

In 2023, Wockhardt's revenue was 28.30 billion, an increase of 6.51% compared to the previous year's 26.57 billion. Losses were -4.63 billion, -17.17% less than in 2022.